TITLE

Reactions to Intravenous Iron Dextran

AUTHOR(S)
Lane, R. S.; Scott, Jean M.
PUB. DATE
February 1965
SOURCE
British Medical Journal;2/13/1965, Vol. 1 Issue 5432, p449
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
No abstract available.
ACCESSION #
64057583

 

Related Articles

  • Clinical Review of the Newer Intravenous Iron Therapy Options. Edwards, Jo H. // Nephrology Nursing Journal;Feb2003, Vol. 30 Issue 1, p70 

    Presents a study which examined the effectiveness of intravenous iron therapy on hemodialysis patients. Background on iron dextran; Methodology; Results of the study.

  • Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. Ricardo Friedrisch, João; Delfini Cançado, Rodolfo // Revista Brasileira de Hematologia e Hemoterapia;Nov/Dec2015, Vol. 37 Issue 6, p400 

    Nutritional iron deficiency anemia is the most common deficiency disorder, affecting more than two billion people worldwide. Oral iron supplementation is usually the first choice for the treatment of iron deficiency anemia, but in many conditions, oral iron is less than ideal mainly because of...

  • Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol. Santosh, Sadashiv; Podaralla, Prashanth; Miller, Brent // NDT Plus;Aug2010, Vol. 3 Issue 4, p341 

    Ferumoxytol is a newly approved preparation of intravenous iron with a modified dextran shell that is thought to confer upon it a low immunogenic potential. Serious adverse reactions have been very uncommon in clinical studies, but these studies excluded patients with prior adverse reactions to...

  • Iron dextran.  // Reactions Weekly;Jul2015, Vol. 1561 Issue 1, p106 

    An abstract of the article "Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron," by E. S. Plummer and colleagues is presented.

  • Beneficial effects of iron therapy in renal failure patients on hemodialysis. fishbane, Steven; Mittal, Sanjeev K.; Maesaka, John K. // Kidney International Supplement;Mar1999, Issue 69, pS-67 

    Examines the beneficial effects of iron therapy on renal failure patients treated with hemodialysis in the United States. Increase in the demand for iron; Reduction of iron stores; Risk associated with intravenous iron dextran therapy.

  • Use of Intravenous Iron Supplementation in Chronic Kidney Disease An Update. Macdougall, Iain C.; Geisser, Peter // Iranian Journal of Kidney Diseases;Jan2013, Vol. 7 Issue 1, p9 

    Iron deficiency is an important clinical concern in chronic kidney disease (CKD), giving rise to iron-deficiency anemia and impaired cellular function. Oral supplementation, in particular with ferrous salts, is associated with a high rate of gastrointestinal side effects and is poorly absorbed,...

  • Parenteral iron products for anemia in end-stage renal disease: Comparative considerations. Bailie, George R. // Formulary;Jun2000, Vol. 35 Issue 6, p498 

    Evaluates available data on parenteral iron preparations for treating iron-deficiency anemia in renal diseases. Capacity of intravenous iron dextran in maintaining and repleting iron stores in hemodialysis; Action of iron gluconate and iron sucrose in enhancing erythropoietin-induced red blood...

  • Sodium Ferric Gluconate Complex in Sucrose: A Safer Alternative.  // Kidney;Sep/Oct99, Vol. 8 Issue 5, p216 

    Discusses an abstract of the article, entitled 'Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans,' by G. Faich and J. Strobosd, published in the 1999 'American Journal of Kidney Diseases'.

  • Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Michael, Beckie; Coyne, Daniel W; Fishbane, Steven; Folkert, Vaughn; Lynn, Robert; Nissenson, Allen R; Agarwal, Rajiv; Eschbach, Joseph W; Fadem, Stephen Z; Trout, J. Richard; Strobos, Jur; Warnock, David G; Ferrlecit Publication Committee // Kidney International;May2002, Vol. 61 Issue 5, p1830 

    Background: Parenteral iron is often required by hemodialysis patients to maintain adequate iron stores. Until recently, the only available form of intravenous iron was iron dextran, which is associated with significant adverse reactions, including anaphylaxis and death. Sodium...

  • Dialysate Iron Therapy: A Potential Alternative to IV Iron Dextran.  // Kidney;Nov/Dec99, Vol. 8 Issue 6, p262 

    Evaluates the safety and efficacy of dialysate iron therapy or infusing soluble ferric pyrophosphate by dialysis, to replenish ongoing iron losses. Stabilization of maintenance dialysis patients receiving erythropoietin with maintenance intravenous (IV) iron dextran; Weekly dose of IV iron...

Share

Read the Article

Other Topics